Eisai and Arena Pharmaceuticals have announced that the FDA has accepted for filing the New Drug Application for an extended...
Pfizer has announced that the FDA has approved Xeljanz XR (tofacitinib citrate) extended-release 11 mg tablets for the once-daily treatment...
The FDA has accepted for review the supplemental new drug application (sNDA) for Trokendi XR (topiramate extended release), from Supernus...
The FDA has approved Adzenys XR-ODT (amphetamine extended release oral), from Neos Therapeutics, for the treatment of ADHD in patients...
Veloxis Pharmaceuticals has announced that once-daily Envarsus XR (tacrolimus extended-release), for the prevention of organ rejection in adult kidney transplant...
Neos Therapeutics, Inc. has announced that the FDA approved Cotempla XR-ODT, the first and only methylphenidate extended-release orally disintegrating tablet...
The FDA has approved Dyanavel XR (amphetamine extended release oral), from Tris Pharma, for the treatment of attention-deficit/hyperactivity disorder (ADHD)...
The FDA has approved Quillivant XR (methylphenidate hydrochloride) from Next Wave Pharma for extended-release oral suspension for treatment of Attention...
Veloxis Pharmaceuticals A/S announced FDA approval of Envarsus XR (tacrolimus extended-release tablets) for the prophylaxis of rejection in kidney transplant...
The FDA has approved Jentadueto XR (linagliptin and metformin hydrochloride extended-release) tablets, from Boehringer Ingelheim and Eli Lilly, for the...